|
1
|
Jemal A, Center MM, DeSantis C and Ward
EM: Global patterns of cancer incidence and mortality rates and
trends. Cancer Epidemiol Biomarkers Prev. 19:1893–1907. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Bosch FX, Ribes J, Cléries R and Díaz M:
Epidemiology of hepatocellular carcinoma. Clin Liver Dis.
9:191–211. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Maronpot RR, Montgomery CA Jr, Boorman GA
and McConnell EE: National toxicology program nomenclature for
hepatoproliferative lesions of rats. Toxicol Pathol. 14:263–273.
1986. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Eustis SL: The sequential development of
cancer: A morphological perspective. Toxicol Lett. 49:267–281.
1989. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Wild CP and Hall AJ: Primary prevention of
hepatocellular carcinoma in developing countries. Mutat Res.
462:381–393. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ogawa K: Molecular pathology of early
stage chemically induced hepatocarcinogenesis. Pathol Int.
59:605–622. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kirpichnikov D, McFarlane SI and Sowers
JR: Metformin: An update. Ann Intern Med. 137:25–33. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Hirsch HA, Iliopoulos D, Tsichlis PN and
Struhl K: Metformin selectively targets cancer stem cells and acts
together with chemotherapy to block tumor growth and prolong
remission. Cancer Res. 69:7507–7511. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Aljada A and Mousa SA: Metformin and
neoplasia: Implications and indications. Pharmacol Ther.
133:108–115. 2012. View Article : Google Scholar
|
|
10
|
Decensi A, Puntoni M, Goodwin P, Cazzaniga
M, Gennari A, Bonanni B and Gandini S: Metformin and cancer risk in
diabetic patients: A systematic review and meta-analysis. Cancer
Prev Res (Phila). 3:1451–1461. 2010. View Article : Google Scholar
|
|
11
|
Algire C, Zakikhani M, Blouin MJ, Shuai JH
and Pollak M: Metformin attenuates the stimulatory effect of a
high-energy diet on in vivo LLC1 carcinoma growth. Endocr Relat
Cancer. 15:833–839. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Bhalla K, Hwang BJ, Dewi RE, Twaddel W,
Goloubeva OG, Wong KK, Saxena NK, Biswal S and Girnun GD: Metformin
prevents liver tumorigenesis by inhibiting pathways driving hepatic
lipogenesis. Cancer Prev Res (Phila). 5:544–552. 2012. View Article : Google Scholar
|
|
13
|
Qu Z, Zhang Y, Liao M, Chen Y, Zhao J and
Pan Y: In vitro and in vivo antitumoral action of metformin on
hepatocellular carcinoma. Hepatol Res. 42:922–933. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Chen HP, Shieh JJ, Chang CC, Chen TT, Lin
JT, Wu MS, Lin JH and Wu CY: Metformin decreases hepatocellular
carcinoma risk in a dose-dependent manner: Population-based and in
vitro studies. Gut. 62:606–615. 2013. View Article : Google Scholar
|
|
15
|
Zheng L, Yang W, Wu F, Wang C, Yu L, Tang
L, Qiu B, Li Y, Guo L, Wu M, et al: Prognostic significance of AMPK
activation and therapeutic effects of metformin in hepatocellular
carcinoma. Clin Cancer Res. 19:5372–5380. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Morimura S, Suzuki T, Hochi S, Yuki A,
Nomura K, Kitagawa T, Nagatsu I, Imagawa M and Muramatsu M:
Trans-activation of glutathione transferase P gene during chemical
hepatocarcinogenesis of the rat. Proc Natl Acad Sci USA.
90:2065–2068. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Saito T, Chiba T, Yuki K, Zen Y, Oshima M,
Koide S, Motoyama T, Ogasawara S, Suzuki E, Ooka Y, et al:
Metformin, a diabetes drug, eliminates tumor-initiating
hepatocellular carcinoma cells. PLoS One. 8:e700102013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Lowes KN, Croager EJ, Olynyk JK, Abraham
LJ and Yeoh GC: Oval cell-mediated liver regeneration: Role of
cytokines and growth factors. J Gastroenterol Hepatol. 18:4–12.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zakikhani M, Dowling R, Fantus IG,
Sonenberg N and Pollak M: Metformin is an AMP kinase-dependent
growth inhibitor for breast cancer cells. Cancer Res.
66:10269–10273. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Rocha GZ, Dias MM, Ropelle ER,
Osório-Costa F, Rossato FA, Vercesi AE, Saad MJ and Carvalheira JB:
Metformin amplifies chemotherapy-induced AMPK activation and
antitumoral growth. Clin Cancer Res. 17:3993–4005. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kourelis TV and Siegel RD: Metformin and
cancer: New applications for an old drug. Med Oncol. 29:1314–1327.
2012. View Article : Google Scholar
|
|
22
|
Memmott RM and Dennis PA: LKB1 and
mammalian target of rapamycin as predictive factors for the
anticancer efficacy of metformin. J Clin Oncol. 27:e226author reply
e227. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhou G, Myers R, Li Y, Chen Y, Shen X,
Fenyk-Melody J, Wu M, Ventre J, Doebber T, Fujii N, et al: Role of
AMP-activated protein kinase in mechanism of metformin action. J
Clin Invest. 108:1167–1174. 2001. View
Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zakikhani M, Dowling RJ, Sonenberg N and
Pollak MN: The effects of adiponectin and metformin on prostate and
colon neoplasia involve activation of AMP-activated protein kinase.
Cancer Prev Res (Phila). 1:369–375. 2008. View Article : Google Scholar
|
|
25
|
Foretz M, Hébrard S, Leclerc J,
Zarrinpashneh E, Soty M, Mithieux G, Sakamoto K, Andreelli F and
Viollet B: Metformin inhibits hepatic gluconeogenesis in mice
independently of the LKB1/AMPK pathway via a decrease in hepatic
energy state. J Clin Invest. 120:2355–2369. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kalender A, Selvaraj A, Kim SY, Gulati P,
Brûlé S, Viollet B, Kemp BE, Bardeesy N, Dennis P, Schlager JJ, et
al: Metformin, independent of AMPK, inhibits mTORC1 in a rag
GTPase-dependent manner. Cell Metab. 11:390–401. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Shaw RJ, Lamia KA, Vasquez D, Koo SH,
Bardeesy N, Depinho RA, Montminy M and Cantley LC: The kinase LKB1
mediates glucose homeostasis in liver and therapeutic effects of
metformin. Science. 310:1642–1646. 2005. View Article : Google Scholar : PubMed/NCBI
|
